Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Battin who wrote (48)	6/19/1998 6:44:00 AM
From: Henry Niman	Respond to of 61

I think that the merger potential is oin SBH's price, but as merger mania continues, price of others continues to climb. WSJ is reporting that an accord has been reached between MRK and Astra. ZEN up in anticipation. Details linked to merger table at home.att.net

To: Mike Battin who wrote (48)	7/10/1998 12:01:00 AM
From: Henry Niman	Respond to of 61

Today Dow Jones had an extensive article on SBH and they did mention the new TZD under development for Type II diabetes. I've linked it to the merger table at home.att.net Tomorrow's Science will have an exciting paper on a G-CSF mimic discovered by scientists at SBH and LGND. I have updated the G-CSF (Neupogen) mimic table at home.att.net to include links to the press release, abstract of the Science article, commentary in Science, and several upcoming abstracts. The current SBH/LGND alliance targets hematopoietic growth factors like Epogen and Neupogen, but recently Leptin was added to the list of targets and I suspect that the target list will continue to grow. Tomorrow's paper is a "proof of principle" that can be applied to virtually any polypeptide hormone (interferons, interleukins, or growth factors) and it is a major event.

To: Mike Battin who wrote (48)	7/28/1998 10:54:00 AM
From: Henry Niman	Respond to of 61

Ruzlin is a TZD that activates a receptor, PPARgamma, that turns on genes which overcome insulin resistance. The activated receptor partners with another hormone receptor, RXRalpha. LGND's and AGN's rexinoids activate RXRalpha. Thus in animal models of type II diabetes, they have been shown to synergize with TZDs like WLA's Rezulin and SBH's Avandia (and TZDs are effective at lower concentrations which may avoid the liver problems). Some details at home.att.net LLY is supposed to begin Phase II clinical trials in the US soon using Targretin as monotherapy (and possibly combination therapy with Rezulin and other approved treatments for diabetes). LLY is also supposed to file INDs for one of LGND's second generation rexinoids (LGD1268 or LGD1324). A few days ago, AGN announced a deal with WLA to develop AGN's rexinoids (LGND gets royalties). The Rezulin problems may have helped seal the AGN/WLA deal. LGND had talked extensively with WLA last summer, but WLA did not want to give LGND up front funds. Consequently, LGND signed a $200 million deal with LLY, including $50 million up front and $75 million tied to early milestones such as starting US trials with Targretin or filing INDs for LGD1268 or LGD1324.

To: Mike Battin who wrote (48)	8/17/1998 8:29:00 AM
From: Henry Niman	Respond to of 61

Bloomberg indicated that GLX trading in Tokyo had been suspended and GLX and SBH denied rumors. Details linked to the merger table at home.att.net

To: Mike Battin who wrote (48)	10/12/1998 8:32:00 AM
From: Henry Niman	Respond to of 61

The GLX/SBH merger rumors are based on a Sunday Times article indicating that Leschley will retire by next year. Details in the WSJ merger table at: biocognizance.com

To: Mike Battin who wrote (48)	10/20/1998 7:35:00 AM
From: Henry Niman	Respond to of 61

Today's Financial Times has renewed speculation on a Leschly resignation. Details in the Merger Mania section of biocognizance.com